Skip to Main Content


Skip Nav Destination

CCR Focus Archive 2011

CCR Focus Archive Home

2017  |  2016  |  2015  |  2014  |  2013  |  2012  |  2011  |  2010  |  2009  |  2008  |  2007  |  2006

Antibody Conjugates: Arming Antibodies to Create Better Anticancer Therapies (October 15, 2011)
A Triple for Prostate Cancer (June 15, 2011)
Progress and Paradigms in Myeloma (March 15, 2011)

2011 CCR Focus Sections

CCR Focus Cover

Antibody Conjugates: Arming Antibodies to Create Better Anticancer Therapies
October 15, 2011
Guest Editor: Beverly A. Teicher, 17 (20) : 6387–6541

Antibody Conjugates: The Future is Now
Susan E. Bates

Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher and Ravi V.J. Chari

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin MoxetumomabPasudotox
Robert J. Kreitman and Ira Pastan

Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Martina Steiner and Dario Neri

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart

Brentuximab Vedotin (SGN-35)
Jessica Katz, John E. Janik, and Anas Younes

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer
Patricia M. LoRusso, Denise Weiss, Ellie Guardino, Sandhya Girish, and Mark X. Sliwkowski

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-cell Malignancies
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz, and John M. Lambert

Back to top

CCR Focus Cover

A Triple for Prostate Cancer
June 15, 2011
Guest Editors: Gerhardt Attard and Johann S. de Bono, 17 (12) : 3866–3812

Prostate Cancer: Score One for Validated Targets
Susan E. Bates

Translating Scientific Advancement into Clinical Benefit for Castration — Resistant Prostate Cancer Patients
Gerhardt Attard and Johann S. de Bono

Targeting Continued Androgen Receptor Signaling in Prostate Cancer
Christophe Massard

Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research
James L. Gulley and Charles G. Drake

Overcoming Chemotherapy Resistance in Prostate Cancer
Ravi A. Madan, Sumanta Kumar Pal, Oliver Sartor, and William L. Dahut

Circulating Tumor Cells as Biomarkers in Prostate Cancer
Daniel C. Danila, Martin Fleisher, and Howard I. Scher

Back to top

CCR Focus Cover

Progress and Paradigms in Myeloma
March 15, 2011
Guest Editor: Kenneth C. Anderson, 17 (6) : 1224–1286

Multiple Myeloma
Susan E. Bates

Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment
Kenneth C. Anderson

Genomics in Multiple Myeloma
Nikhil C. Munshi and Herve Avet-Loiseau

From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention
Ola Landgren, Robert A. Kyle and S. Vincent Rajkumar

Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival
Antonio Palumbo, Michel Attal and Murielle Roussel

Treatment Options for Relapsed and Refractory Multiple Myeloma
Sagar Lonial, Constantine S. Mitsiades, and Paul G. Richardson

Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
Noopur Raje and G. David Roodman

Close Modal

or Create an Account

Close Modal
Close Modal